title: Sirolimus- versus paclitaxel-eluting stents for the treatment of cardiac allograft vasculopathy.
abstract: OBJECTIVE
  The aim of this study was to compare outcomes after percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in the treatment of cardiac allograft vasculopathy (CAV).
  
  
  BACKGROUND
  PCI in patients with CAV is associated with increased rates of restenosis compared with PCI in patients without CAV. There are no dedicated studies on the influence of different drug-eluting stents (DES) on the outcomes of patients with CAV.
  
  
  METHODS
  This is a retrospective observational study of 108 consecutive patients with CAV who underwent PCI with SES and PES at UCLA Medical Center and University of Padova Medical Center between 2002 and 2008.
  
  
  RESULTS
  Baseline characteristics were similar among SES (n = 68) and PES (n = 40) patients with the exception of older patients, larger minimal lumen diameter, and smaller diameter stenosis in the SES-treated patients. Angiographic follow-up at 1 year was high in the SES and PES groups (74% vs. 76%, p = 0.8). The SES and PES groups had similar binary restenosis rates (10% vs. 9%, p = 0.7), percent diameter stenosis (24 +/- 24% vs. 24 +/- 18%, p = 0.94), and late lumen loss (0.67 +/- 1.03 mm vs. 0.68 +/- 1.11 mm, p > 0.9). One-year clinical outcomes were not significantly different among CAV patients treated with either SES or PES (major adverse cardiac events: 10% vs. 15%, p = 0.5; death: 3% vs. 5%, p = 0.4; myocardial infarction: 3% vs. 5%, p = 0.4; target vessel revascularization: 4% vs. 8%, p = 0.3).
  
  
  CONCLUSIONS
  In patients who underwent PCI for CAV, both SES and PES were safe and effective with no significant differences in clinical and angiographic outcomes. Randomized clinical trials comparing different DES with longer follow-up are necessary to identify the optimal treatment strategy for patients with CAV.
authors.affiliation: Division of Cardiology, UCLA Medical Center, Los Angeles, California 90095, USA. mslee@mednet.ucla.edu
authors.forename: Michael S
authors.initials: MS
authors.lastname: Lee
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tarantini
authors.forename: Jola
authors.initials: J
authors.lastname: Xhaxho
authors.forename: Tae
authors.initials: T
authors.lastname: Yang
authors.forename: Ashkan
authors.initials: A
authors.lastname: Ehdaie
authors.forename: Ravi
authors.initials: R
authors.lastname: Bhatia
authors.forename: Enrico
authors.initials: E
authors.lastname: Favaretto
authors.forename: Jonathan
authors.initials: J
authors.lastname: Tobis
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000209:etiology; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D007558:Italy; D015141:Los Angeles; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D017239:Paclitaxel / Q000008:administration & dosage*; D011474:Prosthesis Design; D012189:Retrospective Studies; D012720:Severity of Illness Index; D020123:Sirolimus / Q000008:administration & dosage*; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D017239:Paclitaxel; D020123:Sirolimus